1-20 of 20
Todd Covey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

Subbaiah Chary Nimmagadda, Pradeep Kumar Patnana, Paulina Marie Budde, Helal Ahmed, Todd Covey, Cecile Krejsa, Wayne Rothbaum, Nikolas Von Bubnoff, Cyrus Khandanpour
Journal: Blood
Blood (2023) 142 (Supplement 1): 2782.
https://doi.org/10.1182/blood-2023-174895
Published: 2023
Journal Articles

Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies

Sara Elgamal, Tracy Clevenger, Michael Gulrajani, Jean Cheung, Erin G. Jeremy, Sydney Fobare, Shelley Orwick, Ellen J. Sass, Erin Hertlein, Karilyn T. Larkin, Todd Covey, Wayne P. Rothbaum, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 5936–5938.
https://doi.org/10.1182/blood-2022-159568
Published: 2022
Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Clinical Trials & Observations
Clare Sun, Pia Nierman, Ellen K. Kendall, Jean Cheung, Michael Gulrajani, Sarah E. M. Herman, Christopher Pleyer, Inhye E. Ahn, Maryalice Stetler-Stevenson, Constance M. Yuan, Irina Maric, Erika M. Gaglione, Hailey M. Harris, Stefania Pittaluga, Min Hui Wang, Priti Patel, Mohammed Z. H. Farooqui, Raquel Izumi, Ahmed Hamdy, Todd Covey, Adrian Wiestner
Journal: Blood
Blood (2020) 136 (1): 93–105.
https://doi.org/10.1182/blood.2019003715
Published: 2020
Includes: Supplemental data
Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Clinical Trials & Observations
John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman
Journal: Blood
Blood (2020) 135 (15): 1204–1213.
https://doi.org/10.1182/blood.2018884940
Published: 2020
Includes: Supplemental data
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Richard R. Furman, MD, William G. Wierda, MD PhD, Anna Schuh, Stephen Devereux, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MD PhD, Peter Martin, FRCPC, MD MS, Farrukh T Awan, MD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD MS, John M. Pagel, MD PhD DSc, Jennifer Woyach, MD, Kathleen Burke, PhD, Todd Covey, Michael Gulrajani, Ahmed Hamdy, MD, Raquel Izumi, PhD, Melanie M. Frigault, PhD, Priti Patel, MD, Wayne Rothbaum, Min Hui Wang, PhD, Susan M. O'Brien, MD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3039.
https://doi.org/10.1182/blood-2019-128706
Published: 2019
Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey
Journal: Blood
Blood (2019) 134 (Supplement_1): 2571.
https://doi.org/10.1182/blood-2019-128872
Published: 2019
Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4424.
https://doi.org/10.1182/blood-2018-99-110395
Published: 2018
Journal Articles

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Anfal A. Alsadhan, Jean Cheung, Michael Gulrajani, Erika M. Cook, Stefania Pittaluga, MD PhD, Theresa Davies-Hill, Raquel Izumi, PhD, Clare C. Sun, MD, Todd Covey, PhD, Adrian Wiestner, MD, Sarah E. M. Herman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4401.
https://doi.org/10.1182/blood-2018-99-110391
Published: 2018
Journal Articles

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies

Allard Kaptein, Gerjan de Bruin, Maaike Emmelot-van Hoek, Bas van de Kar, Anouk de Jong, Michael Gulrajani, Dennis Demont, Todd Covey, PhD, Diana Mittag, Tjeerd Barf
Journal: Blood
Blood (2018) 132 (Supplement 1): 1871.
https://doi.org/10.1182/blood-2018-99-109973
Published: 2018
Journal Articles

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Mojgan Jianfar, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD MPH, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, John C. Byrd, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 432.
https://doi.org/10.1182/blood.V130.Suppl_1.432.432
Published: 2017
Journal Articles

Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study

Todd Covey, PhD, Michael Gulranjani, Jean Cheung, Elena Bibikova, Tracy Clevenger, Fanny Krantz, Karen Pan, Kyoko Yamaguchi, Anouk De Jong, Bart Van Lith, Diana Mittag, Raquel Izumi, PhD, John C. Byrd, MD, William G Wierda, MD PhD, Susan M. O'Brien, MD, Richard R. Furman, MD, Allard Kaptein, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1741.
https://doi.org/10.1182/blood.V130.Suppl_1.1741.1741
Published: 2017
Journal Articles

Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

Michael Wang, MD, Simon Rule, MD, Pier Luigi Zinzani, MD PhD, Andre Goy, MD, Rene-Olivier Casasnovas, MD, Stephen D. Smith, MD, Gandhi Damaj, MD, Jeanette K. Doorduijn, MD PhD, Thierry Lamy, Pr, MD PhD, Franck Morschhauser, MD PhD, Carlos Panizo, MD PhD, Bijal Shah, MD, Andrew Davies, PhD, Richard Eek, MBCHB, Jehan Dupuis, MD, Eric Jacobsen, MD, Arnon P. Kater, MD PhD, Steven Le Gouill, MDPhD, Lucie Oberic, MD, Tadeusz Robak, MD PhD, Todd Covey, PhD, Richa Dua, PharmD, Ahmed Hamdy, MD, Xin Huang, Raquel Izumi, PhD, Priti Patel, MD, J. Greg Slatter, PhD, Wojciech Jurczak, PhDMD
Journal: Blood
Blood (2017) 130 (Supplement 1): 155.
https://doi.org/10.1182/blood.V130.Suppl_1.155.155
Published: 2017
Journal Articles

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Arnau Montraveta, BS, Carsten U Niemann, MD PhD, Helena Mora-Jensen, PhD, Michael Gulrajani, BS, Fanny Krantz, Bonnie K. Harrington, DVM, Todd Covey, Brian J Lannutti, PhD, Raquel Izumi, PhD, Roger G Ulrich, PhD, John C. Byrd, MD, Adrian Wiestner, MD PhD, Amy J. Johnson, PhD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2015) 126 (23): 2920.
https://doi.org/10.1182/blood.V126.23.2920.2920
Published: 2015
Journal Articles

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

Bonnie K. Harrington, DVM, Michael Gulrajani, BS, Todd Covey, Allard Kaptein, PhD, Bart Van Lith, Raquel Izumi, PhD, Ahmed Hamdy, MBBCh, Roger Glenn Ulrich, PhD, John C Byrd, MD, Brian J Lannutti, PhD, Amy J. Johnson, PhD
Journal: Blood
Blood (2015) 126 (23): 2908.
https://doi.org/10.1182/blood.V126.23.2908.2908
Published: 2015
Journal Articles

The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile

John C. Byrd, MD, William Wierda, MD PhD, Jeffrey Jones, MD MPH, Susan O'Brien, MD, Jennifer R. Brown, MD PhD, Anna Schuh, MD PhD, Peter Hillmen, MB, ChB, PhD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Steve Devereux, MD, Jorge M. Chaves, MD, Jacqueline C. Barrientos, MD, Min Hui Wang, PhD, Jane Huang, MD, Todd Covey, Tasheda Navarro, Wayne Rothbaum, Raquel Izumi, PhD, Ahmed Hamdy, MBBCh, Richard R. Furman, MD
Journal: Blood
Blood (2015) 126 (23): 831.
https://doi.org/10.1182/blood.V126.23.831.831
Published: 2015
Journal Articles

Defective Nucleotide Metabolism Contributes To p53 Activation In Diamond-Blackfan Anemia

Nadia Danilova, Ph.D, Bibikova Elena, Todd Covey, David Nathanson, Elizabeth Dimitrova, Lindgren Anne, Bertil Glader, M.D., Ph.D, Caius Radu, Kathleen Sakamoto, Shuo Lin
Journal: Blood
Blood (2013) 122 (21): 1225.
https://doi.org/10.1182/blood.V122.21.1225.1225
Published: 2013
Journal Articles

Single Cell Network Profiles in Non-M3 AML Associated with Patient Response to Standard Induction Therapy.

Steven Kornblau, M.D., M. D. Minden, MD, PhD, David B. Rosen, PhD, Santosh Putta, PhD, Aileen C. Cohen, MD, PhD, Todd Covey, Wendy J. Fantl, PhD, Urte Gayko, PhD, Alessandra Cesano, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1582.
https://doi.org/10.1182/blood.V114.22.1582.1582
Published: 2009
Journal Articles

Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure.

Alessandra Cesano, MD, PhD, John Woronicz, PhD, Aileen Cleary Cohen, MD, PhD, Todd Covey, Santosh Putta, PhD, Urte Gayko, PhD, Wendy J. Fantl, PhD, S.M. Kornblau, M.D.
Journal: Blood
Blood (2009) 114 (22): 397.
https://doi.org/10.1182/blood.V114.22.397.397
Published: 2009
Journal Articles

Classification of Acute Myeloid Leukemia (AML) Based On Apoptosis and Myeloid Signaling Networks.

David B. Rosen, PhD, M. D. Minden, MD, PhD, Santosh Putta, PhD, Todd Covey, Ying W. Huang, MSc, Alessandra Cesano, MD, PhD, Wendy J. Fantl, PhD
Journal: Blood
Blood (2009) 114 (22): 325.
https://doi.org/10.1182/blood.V114.22.325.325
Published: 2009
Journal Articles

Distinct Proteomic Signaling Networks Stratify Responses to Ara-C Based Induction Therapy in Patients with Acute Myeloid Leukemia (AML)

Mark Minden, David Rosen, Santosh Putta, Aileen Cohen, Helen Francis-Lang, Todd Covey, John Woronicz, David Soper, Brian Long, James Cordeiro, Lootsie Panganiban-Lustan, Steve Banville, Urte Gayko, Alessandra Cesano, Wendy Fantl
Journal: Blood
Blood (2008) 112 (11): 2549.
https://doi.org/10.1182/blood.V112.11.2549.2549
Published: 2008